Yury Kukushkin
Direttore/Membro del Consiglio presso Veralox Therapeutics, Inc.
Profilo
Yury Kukushkin became a Managing Director for the T1D Fund in 2022 after joining as an Investment Director in 2019 from 4BIO Capital, a London-based fund investing in public and private life sciences companies.
While there, he focused on gene and cell therapies, PROTACs, RNA medicines, and targeted therapies and delivered top quartile returns for the fund.
Prior to this role, Yury was Chief Analyst and Associate at RBV Capital, an early-stage life sciences venture fund.
Earlier in his career, Yury worked in various roles in a boutique consulting company Abercade supporting over 20 various investment deals with US-based venture-backed companies.
Originally from Moscow, Russia, Yury received his M.S.
in Biochemistry with specialization in Virology from Moscow State University and a Ph.D.
in Cellular Biochemistry from Max Planck Institute of Biochemistry, Martinsried, Germany.
Posizioni attive di Yury Kukushkin
| Società | Posizione | Inizio |
|---|---|---|
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Direttore/Membro del Consiglio | 01/12/2020 |
Code Biotherapeutics, Inc.
 Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/03/2021 |
| Hevolution Foundation | Corporate Officer/Principal | 01/09/2023 |
Precedenti posizioni note di Yury Kukushkin
| Società | Posizione | Fine |
|---|---|---|
| 4bio Capital Partners | Investitore di Private Equity | 01/09/2023 |
JDRF T1D Fund
 JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Investitore di Private Equity | 01/09/2023 |
Formazione di Yury Kukushkin
| Moscow State University Lomonosov | Masters Business Admin |
| Max Planck Institute of Biochemistry | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
| 4bio Capital Partners | Finance |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Finance |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
| Hevolution Foundation |
- Borsa valori
- Insiders
- Yury Kukushkin
